Fujisawa Workshop on Empiric Oral Therapy for Today's Community-Acquired Infections at 2nd European Congress of Chemotherapy Industry Symposium, Hamburg, Germany, 12 May 1998: Overview of the clinical features of cefixime

Chemotherapy

Volumn 44, Issue SUPPL. 1, 1998, Pages 1-5

  Adam, Dieter ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

3rd Gen. cephalosporin; Bacterial infection; Cefixime

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAMASE; CEFACLOR; CEFIXIME; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN;

BACTERIAL INFECTION; CLINICAL FEATURE; CONFERENCE PAPER; DRUG EFFICACY; DRUG HALF LIFE; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; PRIORITY JOURNAL; SKIN MANIFESTATION; STREPTOCOCCUS PNEUMONIAE; WORKSHOP;

EID: 0031695159     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (5)

1. Barry AL: Antimicrobial agents for community-acquired respiratory tract infections. Infection 1995; 23(suppl 2):59-64.
2. New HC, Chick TW: Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections. Chest 1993;104:1393-1399.
3. Adam D: Cefixime study group: 5-day cefixime therapy for bacterial pharyngitis and/or tonsillitis: Comparison with 10-day penicillin V therapy. Infection 1995;23(suppl 2): 83-86.
4. Adam D, Hostalek U: Cefixime study group: Efficacy and tolerance of cefixime as compared to penicillin V in children with bacterial pharyngitis and tonsillitis. Clin Pediatr 1994;206:26-29.
5. Adam D, Hostalek U, Tröster K: Cefixime study group: 5-day treatment of bacterial pharyngitis and tonsillitis with cefixime. Comparison with a 10-day treatment with penicillin V. Clin Pediatr 1996;208: 310-313.